CompletedNot Applicable

Validation the Artificial Intelligence System for Automatic Evaluation of the Extent of Intestinal Metaplasia

China1,080 participantsStarted 2022-07-01

Plain-language summary

The operative link on gastric intestinal metaplasia assessment (OLGIM) staging systems using biopsy specimens were commonly used for histological assessment of gastric cancer risk. But its clinical application is limited for at least biopsy samples. The endoscopic grading system (EGGIM) has been shown a significant correlation with the OLGIM. The investigators designed a computer-aided diagnosis program using deep neural network to automatically evaluate the extent of IM and calculate the EGGIM scores in endoscopy examination. This study is aimed at exploring the relevance of the EGGIM scores automatically evaluated by Artificial Intelligence and OLGIM scores.

Who can participate

Age range40 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients aged 40-75 years who undergo the IEE examination Exclusion Criteria: * patients with severe cardiac, cerebral, pulmonary or renal dysfunction or psychiatric * disorders who cannot participate in gastroscopy * patients with previous surgical procedures on the stomach * patients with contraindications to biopsy * patients who refuse to sign the informed consent form

What they're measuring

Accuracy of AI model to diagnose extensive intestinal metaplasia (OLGIM stage III/IV) by calculating the EGGIM score

Timeframe: 2 years

Trial details

NCT IDNCT05464108

SponsorShandong University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-12-30

View on ClinicalTrials.gov More Intestinal Metaplasia of Gastric Mucosa trials